Status unknownNCT01946451Updated Sep 19, 2013

Gene Expression in Patients With Epiretinal Membranes

An observational study in Proliferative Diabetic Retinopathy, sponsored by Medical University of Silesia. Status unknown at 1 site in Poland. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2013-09-19.

Sponsored by Medical University of Silesia · Observational

The sponsor has not verified this record recently (last verified Sep 2013), so the status shown — last known as Active, not recruiting — may be out of date.

Study type: Observational
Model: Case-control
Time perspective: Retrospective
Ages: 55 Years and older
Sex: All

Study summary

The purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (ERMs) and peripheral blood mononuclear cells (PBMCs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. Possible correlations between messenger ribonucleic acid (mRNA) levels of these genes were also identified.

Conditions studied

Proliferative Diabetic Retinopathy

Keywords

idiopathic epiretinal membranes
secondary epiretinal membranes

In context

Lead sponsor

Medical University of Silesia is the lead sponsor of 113 studies on the registry; 24 are open to participants now.

Browse Medical University of Silesia studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 55 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Study population description:

The blood and ERM samples were obtained from patients treated in the Department of Ophthalmology, University Hospital No. 5, Medical University of Silesia, Katowice, Poland.

All subjects underwent a complete ophthalmic examination: best corrected visual acuity (BCVA), tonometry, slit lamp examination of anterior and posterior segment, optical coherence tomography (OCT) of the central retina.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Caucasian race,
both males and females,
aged ≥ 55 years,
suffering from idiopathic ERMs or secondary ERMs in proliferative diabetic retinopathy (PDR).
Presence of ERM was proven in optical coherence tomography (OCT) examination.

Exclusion criteria

Exclusion criteria:

aged \< 55 years,
systemic connective tissue disease,
active inflammatory process

Study design

Observational model: Case-control
Time perspective: Retrospective
Patient registry: No

Groups and cohorts

Idiophatic ERMs
Secondary ERMs

What researchers measure

Primary outcomes

Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.
Time frame: The period between the diagnosis of the ERMs and the actual surgery for the condition was between 2 and 43 months.

Study locations

1 site

Medical University of Silesia
Katowice, Poland

Timeline

Tracking since Sep 25, 2026

Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Sep 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered: Sep 16, 2013
First posted: Sep 19, 2013
Start: Jun 2012
Primary completionActual: Sep 2013
CompletionEst.: Dec 2013
Last update: Sep 19, 2013

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Sep 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01946451
Lead sponsor: Medical University of Silesia
Responsible party: Dorota Romaniuk (MD, Medical University of Silesia) — Principal investigator
First posted: Sep 19, 2013
Start date: Jun 2012
Primary completion: Sep 2013
Completion: Dec 2013 (estimated)
Last update: Sep 19, 2013

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Medical University of Silesia →

Start the discussion